SCHEMBL25575429

SCHEMBL25575429

CC(C)(C)OC(=O)NCCOCCCc1ccc(Br)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.46
CA2 P00918 4/20 0.46
DDB1 Q16531 1/20 0.45
CRBN Q96SW2 1/20 0.45
IDO1 P14902 1/20 0.44
CTSS P25774 1/20 0.44
CTSK P43235 1/20 0.44
SIGMAR1 Q99720 2/20 0.43
FPR3 P25089 4/20 0.43
FPR2 P25090 4/20 0.43
KDM4E B2RXH2 1/20 0.43
GLA P06280 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CA12 O43570 2/20 0.43
CA9 Q16790 2/20 0.43
NAMPT P43490 1/20 0.42
SUCNR1 Q9BXA5 1/20 0.42
USP2 O75604 1/20 0.42
LMNA P02545 1/20 0.42
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23728795 0.89 CA1 (0.47) CA1CA2DDB1CRBNIDO1
SCHEMBL2551512 0.88 CA1 (0.53) CA1CA2CTSSCTSKSIGMAR1
SCHEMBL21482939 0.87 TDP1 (0.53) CA1CA2CTSSCTSKSIGMAR1
SCHEMBL25301986 0.85 IDO1 (0.47) CA1CA2IDO1CTSSCTSK
SCHEMBL1065312 0.85 CA2 (0.55) CA1CA2CTSSCTSKFPR3
SCHEMBL20506786 0.84 CA2 (0.54) CA1CA2DDB1CRBNIDO1
SCHEMBL31584155 0.82 CA12 (0.60) CA1CA2IDO1FPR3FPR2
SCHEMBL30958195 0.81 IDO1 (0.48) CA1CA2IDO1CA12CA9
SCHEMBL24812650 0.80 CA1 (0.54) CA1CA2DDB1CRBNIDO1
SCHEMBL25772085 0.79 SIGMAR1 (0.56) CA1CA2IDO1SIGMAR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230381326-A1 DRUG DELIVERY SYSTEM FOR TREATING DISEASE SDG, LLC 2023-11-30 US disclosed
US-11666654-B2 Drug delivery system for treating disease SDG LLC (US) 2023-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11666654-B2 Drug delivery system for treating disease HPGDS, VHL, HPSE CA1 1007/4885CA2 636/4885DDB1 4596/4885
US-20230381326-A1 DRUG DELIVERY SYSTEM FOR TREATING DISEASE HPGDS, VHL, HPSE CA1 1007/4885CA2 636/4885DDB1 4596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.